Evidence map›Paper›PMID 8588125›Full record

Trial reportRheumatology international1995

Characterization of B-cell lines from SLE patients and their relatives.

T Witte, K Hartung, F M Bode, R E Schmidt, H Deicher

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Rheumatology international, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

T WitteHarvard Medical School, Dana-Farber Cancer Institute, Division of Immunology, Boston, MA 02115, USA.
K Hartung
F M Bode
R E Schmidt
H Deicher
Medizinische Hochschule Hannover · DEHarvard University · USKlinikum Bremerhaven-Reinkenheide · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr-virus (EBV)-transformed lymphoblastoid B-cell lines were generated from peripheral blood lymphocytes of 55 patients with systemic lupus erythematosus (SLE) and 44 healthy relatives. All donors have previously been extensively characterized with regard to clinical, serologic, and genetic parameters. Here, peripheral blood lymphocytes and lines were characterized for cell surface antigens. Furthermore, autoantibody production and proliferation rate of the cell lines were monitored. A significant difference between patients and relatives was the lower proliferation rate of EBV-transformed cell lines of the SLE patients. All SLE cell lines are available for interested researches and can be obtained from the European Cell Bank, Salisbury, UK.

Indexed as

Antigens, SurfaceB-LymphocytesCell DivisionCell Line, TransformedFluorescent Antibody Technique, IndirectHerpesvirus 4, HumanHumansImmunoglobulinsLupus Erythematosus, SystemicNuclear FamilyAntigens, SurfaceImmunoglobulins

Identifiers

PMID8588125
OpenAlexW2045877654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.